Elutia, Inc. (ELUT) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

10/25

Growth 2 Margin 3 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

10
Elutia (ELUT) Q2 2026: Secures $26M Funding, Validates Surgeons’ Demand Ahead of NXT-41x Launch
August 17, 2026
14
ELUT Q1 2026: NXT 41X FDA Pathway Lifts Confidence as 80% Margin Platform Scales
June 17, 2026
19
ELUT Q2 2025: LU Pro Drives 49% Sequential Growth, Margin Expansion Signals Scalable Platform
June 16, 2026
12
Elutia (ELUT) Q3 2025: $88M Divestiture Fuels NXT41X Launch Path and Margin Reset
June 16, 2026
12
Ellucia (ELUT) Q4 2025: Gross Margin Expands 12 Points as Strategic Reset Focuses on 41X Launch
June 15, 2026
12
Elutia (ELUT) Q1 2025: EluPro Sales Surge 84% Sequentially, Fueling BioEnvelope Growth and Operational Expansion
May 08, 2025
Elutia (ELUT) Q4 2024: EluPro Drives 18% BioEnvelope Sales Growth Amid Accelerated Market Penetration
March 06, 2025

Browse all companies